Her2 s310f specific antigen-binding molecules
OwnerTatsushi KODAMA, Yang SUNinventors
Life of this patent
Estimating the term…
Abstract
An objective of the present invention is to provide antigen-binding molecules that specifically bind to HER2 mutant. The present invention provides antigen-binding molecules that specifically bind to HER2 mutant, and are capable of modulating and/or activating an immune response; compositions comprising the antigen-binding molecule; and methods of using the same.
Claims24
An antigen-binding molecule comprising a first antigen-binding domain which specifically binds to human HER2 with S310F mutation (HER2 S310F) but does not bind to wild type human HER2.
(canceled)
(canceled)
A host cell comprising the nucleic acid of claim 18.
The method of claim 20 wherein the cancer is characterized by expression of HER2 S310F.
The method of claim 24 wherein the cancer is:
- bladder cancer, cervical cancer, colorectal cancer (CRC), non-small-cell lung cancer (NSCLC), esophagus cancer, head and neck cancer, skin cancer (melanoma), bile duct cancer, kidney cancer, stomach cancer, small intestine cancer, liver cancer, uterus cancer, duodenum cancer, breast cancer, or gall bladder cancer.
Dependencies are inferred from the claim text.